Sugi Predict

Sugi Predict / Compounds / SCHEMBL4043322

SCHEMBL4043322

SCHEMBL4043322

CCc1c(OC)cccc1C(=O)NN1C(c2ccccc2)=NOC12CCCC2

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.39
▸ MEN1 O00255 3/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ FAAH O00519 1/20 0.38
▸ CNR2 P34972 1/20 0.38
▸ HCN4 Q9Y3Q4 3/20 0.37
▸ HCN1 O60741 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ FABP3 P05413 1/20 0.35
▸ FABP4 P15090 1/20 0.35
▸ FABP5 Q01469 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ ITGB1 P05556 3/20 0.34
▸ ITGA4 P13612 3/20 0.34
▸ ITGB7 P26010 2/20 0.34
▸ ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4222252 0.93 P2RX7 (0.38) KMT2AMEN1ALDH1A1FAAHCNR2
SCHEMBL4039303 0.90 HCN4 (0.34) KMT2AMEN1ALDH1A1HCN4
SCHEMBL4209748 0.85 FAAH (0.37) FAAHCNR2TP53FABP3FABP4
SCHEMBL4215610 0.85 HTT (0.38) ALDH1A1FAAHCNR2TP53ADORA3
SCHEMBL4212749 0.83 P2RX7 (0.35) HCN4
SCHEMBL4211507 0.79 P2RX7 (0.38) KMT2AMEN1ALDH1A1
SCHEMBL4212824 0.78 NPC1 (0.38) KMT2AALDH1A1FAAHCNR2TP53
SCHEMBL4217655 0.77 SYK (0.35) TP53
SCHEMBL4216157 0.75 NPC1 (0.33) TP53
SCHEMBL4216949 0.75 MEN1 (0.37) KMT2AMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895306-B2 Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex INTREXON CORPORATION (US) 2014-11-25 — — US claimed
US-8669072-B2 Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex INTREXON CORPORATION (US) 2014-03-11 — — US claimed
EP-1601354-B1 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX INTREXON CORP (US) 2013-11-13 — — EP claimed
EP-1601354-A4 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX INTREXON CORP (US) 2009-08-12 — — EP claimed
US-20090149514-A1 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX INTREXON CORPORATION 2009-06-11 — — US claimed
US-20080255210-A1 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system HORMANN ROBERT EUGENE 2008-10-16 — — US claimed
US-20070287731-A1 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system RHEOGENE, INC. (DE CORPORATION) 2007-12-13 — — US claimed
US-7304162-B2 Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide INTREXON CORPORATION (US) 2007-12-04 — — US claimed
EP-1601354-A2 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RheoGene Holdings Inc. (US) 2005-12-07 — — EP claimed
WO-2005017126-A2 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX RHEOGENE HOLDINGS, INC. (US) 2005-02-24 — — WO claimed
US-20040171651-A1 Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide RHEOGENE, INC. (DE CORPORATION) 2004-09-02 — — US claimed
US-20170275600-A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A INTREXON CORPORATION (US) 2017-09-28 — — US disclosed
US-9677055-B2 Modified forms of Pseudomonas exotoxin A INTERXON CORPORATION (US) 2017-06-13 — — US disclosed
US-20170037386-A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A INTREXON CORPORATION (US) 2017-02-09 — — US disclosed
US-9447387-B2 Modified forms of pseudomonas exotoxin A INTREXON CORPORATION (US) 2016-09-20 — — US disclosed
US-9371517-B2 Modified forms of Pseudomonas exotoxin A INTREXON CORPORATION (US) 2016-06-21 — — US disclosed
US-20160108377-A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A INTREXON CORPORATION (US) 2016-04-21 — — US disclosed
US-20150291941-A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A INTREXON CORPORATION (US) 2015-10-15 — — US disclosed
US-8932586-B2 Modified forms of Pseudomonas exotoxin A INTREXON CORPORATION (US) 2015-01-13 — — US disclosed
US-20130121983-A1 Modified Forms of Pseudomonas Exotoxin A INTREXON CORPORATION (US) 2013-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287731-A1 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system NR0B1, NR0B2, NR5A2 KMT2A 3011/4885MEN1 4614/4885ALDH1A1 3889/4885
US-20170275600-A1 MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A CD4, CD47, CD14 KMT2A 2781/4885MEN1 3041/4885ALDH1A1 4812/4885
US-20080255210-A1 1-Benzyl-3-[3-(3,5-dimethyl-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-urea; nuclear receptor-based inducible gene expression system NR0B1, NR0B2, NR5A2 KMT2A 3011/4885MEN1 4614/4885ALDH1A1 3889/4885
US-20040171651-A1 Regulating and tailoring expression levels; such as N-[3-(4-chloro-phenyl)-5,5-dimethyl-[1,2,4]oxadiazol-4-yl]-3-ethyl-benzamide NR2E3, ESRRB, NR0B2 KMT2A 1246/4885MEN1 4391/4885ALDH1A1 4171/4885
US-20090149514-A1 OXADIAZOLINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX ESRRB, NR2E3, NR5A1 KMT2A 3412/4885MEN1 4367/4885ALDH1A1 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.